Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

60.70 -4.90 (-7.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,057,322
Open 65.55
Bid (Size) 54.00 (5)
Ask (Size) 62.50 (1)
Prev. Close 65.60
Today's Range 59.52 - 65.55
52wk Range 47.88 - 107.37
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire

Performance

YTD
-22.9%
-22.9%
1 Month
-3.1%
-3.1%
3 Month
-20.9%
-20.9%
6 Month
-25.5%
-25.5%
1 Year
-9.4%
-9.4%

More News

Read More
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
From Arcellx, Inc.
Via Business Wire
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Via Benzinga
(ACLX) - Analyzing Arcellx's Short Interest
Via Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Via Benzinga
14 Analysts Have This To Say About Arcellx
Via Benzinga
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Via Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Via Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire
Analyst Expectations For Arcellx's Future
Via Benzinga
Navigating 7 Analyst Ratings For Arcellx
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
Via Benzinga
4 Analysts Assess Arcellx: What You Need To Know
Via Benzinga
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire
Assessing Arcellx: Insights From 7 Financial Analysts
Via Benzinga
Decoding 8 Analyst Evaluations For Arcellx
Via Benzinga
The Latest Analyst Ratings For Arcellx
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily

Frequently Asked Questions

Is Arcellx, Inc. - Common Stock publicly traded?
Yes, Arcellx, Inc. - Common Stock is publicly traded.
What exchange does Arcellx, Inc. - Common Stock trade on?
Arcellx, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcellx, Inc. - Common Stock?
The ticker symbol for Arcellx, Inc. - Common Stock is ACLX on the Nasdaq Stock Market
What is the current price of Arcellx, Inc. - Common Stock?
The current price of Arcellx, Inc. - Common Stock is 60.70
When was Arcellx, Inc. - Common Stock last traded?
The last trade of Arcellx, Inc. - Common Stock was at 04/01/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.